Home › Companies › ELOX

Eloxx Pharmaceuticals

ELOX Rare disease Lead: Phase 2 1 Biotech Distilled article ↓

Renal Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (4 active programs)

exaluren

Small Molecule Target: ribosome, COL4A3, COL4A4, COL4A5, PKD1, PKD2

Alport Syndrome Phase 2 subcutaneous
Autosomal Dominant Polycystic Kidney Disease Preclinical

ZKN-013

Small Molecule Target: ribosome, COL7A1, LAMB3

Recessive Dystrophic Epidermolysis Bullosa Phase 1 oral Almirall
Junctional Epidermolysis Bullosa Phase 1 oral Almirall

Biotech Distilled coverage (1)

2026-06-18 Eloxx Pharmaceuticals (ELOX) — Scientific Deep Dive for Exaluren and the Ribosomal Readthrough Pipeline

Articles open on Substack. Some deep dives are subscriber-only.